Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of semaglutide, affecting the majority of people at some point during treatment, particularly after starting or moving up a dose. In the STEP 1 trial, published in the New England Journal of Medicine, around 44% of participants on semaglutide 2.4mg experienced nausea compared with 16% on placebo — it is real, well-documented, and for most people, manageable. The good news is that a handful of practical measures, and in some cases over-the-counter medicines, meaningfully reduce it. This page explains what the evidence and NHS clinical guidance actually support, so you can discuss the right approach with your prescriber rather than guessing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP programme established that gastrointestinal side effects (nausea chief among them) are a predictable feature of semaglutide treatment, not a sign something has gone wrong. The NHS semaglutide medicines page lists nausea, vomiting, diarrhoea, constipation, and indigestion as common effects, and notes they are typically worst immediately after a dose increase. The mechanism is understood: Wegovy slows gastric emptying, which is exactly how it reduces appetite, but it also means food sits in the stomach longer and nausea follows.
Crucially, severity tends to follow a curve. Most people find it peaks in the first week of a new dose and then recedes. Knowing that helps, it is not a sign that treatment is failing or that you need to stop. That said, a minority of people do experience nausea severe enough to disrupt daily life, and for them a structured approach, including antiemetic medicines, is worth a proper conversation with their prescriber, and our page on the best anti-nausea medication for Wegovy is a good place to start thinking about which options suit you. Explore the fuller picture of Wegovy's side effects if you want context beyond nausea alone.
There is no antiemetic that has been specifically trialled or licensed for GLP-1-related nausea in the UK. What exists is a short list of over-the-counter and prescription antiemetics that clinicians draw on in practice, each with a different mechanism and profile.
Cyclizine is an antihistamine antiemetic available over the counter in UK pharmacies. It acts centrally to dampen the brain's vomiting reflex and can be useful for nausea without a strong gastric component. It does not interact with the delayed gastric emptying that Wegovy causes, which makes it a practical first option that prescribers often suggest. Promethazine (sold as Phenergan) works similarly and can also be purchased from a pharmacy, though it causes drowsiness in most people, worth knowing before your first dose.
For nausea with a more pronounced gastric component (the heavy, full feeling) domperidone is a prescription medicine that works by speeding gastric emptying slightly. This is specifically relevant for Wegovy's mechanism, though it requires a prescriber and carries its own contraindications. Metoclopramide (Maxolon) is another option occasionally used for short-term nausea management, again on prescription. Both domperidone and metoclopramide are not something to self-source; discuss them explicitly with your prescriber if over-the-counter options are not providing enough relief. For more detail on specific medicines and how they sit alongside semaglutide, see our dedicated page on taking anti-nausea medicine with Wegovy.
Ginger (whether as tea, capsules, or biscuits) has modest evidence behind it from general nausea research, including chemotherapy-related and motion-sickness contexts. It will not eliminate semaglutide nausea, but it is safe, widely available, and some people find it takes the edge off. A one-minute habit worth trying: check the ingredients on any ginger supplement you buy; a few contain additives that can themselves aggravate an unsettled stomach.
Non-pharmacological strategies often make as much difference as antiemetics, and they have no side effects of their own. The most consistent advice from clinical guidance and patient experience alike centres on three things: injection timing, portion size, and eating speed.
Injecting at a time when you can rest for a couple of hours afterwards reduces the impact of the peak absorption period. Many people find evening injections work better for them, since any nausea tends to arrive overnight when they are asleep. Our page on the best time to take Wegovy to reduce nausea goes through this in more detail.
Portion sizes matter more than food choices. Wegovy slows your stomach significantly; a meal that would previously have felt comfortable can feel overwhelming on treatment. Smaller, more frequent meals (five or six times a day rather than three) give your stomach less to process at once. Eating slowly compounds this: rapid eating inflates the stomach quickly, which worsens the sensation of fullness that tips into nausea. High-fat and highly spiced foods tend to trigger or worsen symptoms more than plain, lower-fat options. This is not a permanent restriction, as your body adjusts to the medicine, tolerance usually improves. For a fuller look at what to eat and what to avoid, our guidance on managing nausea on Wegovy covers dietary strategies in detail.
Hydration is often underrated. Nausea suppresses thirst, and mild dehydration then makes nausea worse. Small, frequent sips of water or a dilute electrolyte drink are easier on a queasy stomach than large glasses.
Most Wegovy nausea is unpleasant without being dangerous. These signs mean you should contact your prescriber or seek urgent medical attention:
Severe, persistent stomach pain that radiates to the back (with or without vomiting) should be assessed promptly, as this can be a sign of pancreatitis, a known but infrequent risk with GLP-1 medicines highlighted in the MHRA's Drug Safety Update communications. Do not wait to see whether it resolves.
Vomiting or nausea severe enough to stop you keeping fluids down for more than 24 hours carries a risk of dehydration. Persistent dehydration can affect kidney function. Contact your prescriber if this happens rather than adjusting your dose independently.
Signs of an allergic reaction (swelling of the face, lips or throat, difficulty breathing, or a severe rash) require emergency services (999), not a call to your pharmacy.
If you have concerns that fall short of an emergency, our guidance on taking Wegovy when you feel unwell addresses some of the day-to-day decisions around pausing or continuing treatment. You can also report suspected side effects directly to the MHRA using the Yellow Card scheme, it is quick, anonymous, and genuinely valuable for ongoing medicines monitoring.
If you are at the stage of deciding whether Wegovy is right for you, or want to discuss your side-effect history with a clinician before starting, start your free consultation with our prescribers. Side effects, including how to manage nausea, are covered as a standard part of every assessment at our GPhC-registered pharmacy.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.